دورية أكاديمية

Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales.

التفاصيل البيبلوغرافية
العنوان: Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales.
المؤلفون: Simner PJ; Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Beisken S; Ares Genetics, Vienna, Austria., Bergman Y; Division of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Ante M; Ares Genetics, Vienna, Austria., Posch AE; Ares Genetics, Vienna, Austria., Tamma PD; Division of Pediatric Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
المصدر: Microbial drug resistance (Larchmont, N.Y.) [Microb Drug Resist] 2022 Feb; Vol. 28 (2), pp. 161-170. Date of Electronic Publication: 2021 Oct 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Mary Ann Liebert Country of Publication: United States NLM ID: 9508567 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1931-8448 (Electronic) Linking ISSN: 10766294 NLM ISO Abbreviation: Microb Drug Resist Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Larchmont, N.Y. : Mary Ann Liebert, c1995-
مواضيع طبية MeSH: Anti-Bacterial Agents/*pharmacology , Carbapenem-Resistant Enterobacteriaceae/*genetics , Cephalosporins/*pharmacology , Genes, Bacterial/*genetics, Drug Resistance, Multiple, Bacterial ; Microbial Sensitivity Tests ; Whole Genome Sequencing ; beta-Lactamases/genetics ; Cefiderocol
مستخلص: The objective of this study was to identify putative mechanisms contributing to baseline cefiderocol resistance among carbapenem-resistant Enterobacterales (CRE). We evaluated 56 clinical CRE isolates with no previous exposure to cefiderocol. Cefiderocol and comparator agent minimum inhibitory concentrations (MICs) were determined by broth microdilution. Short-read and/or long-read whole genome sequencing was pursued. Cefiderocol nonwild type (NWT; i.e., MICs ≥4 mg/L) CRE were compared with species-specific reference genomes and with cefiderocol wild type (WT) CRE isolates to identify genes or missense mutations, potentially contributing to elevated cefiderocol MICs. A total of 14 (25%) CRE isolates met cefiderocol NWT criteria. Of the 14 NWT isolates, various β-lactamases ( e.g., carbapenemases in Klebsiella pneumoniae and AmpC β-lactamases in Enterobacter cloacae complex) in combination with permeability defects were associated with a ≥ 80% positive predictive value in identifying NWT isolates. Unique mutations in the sensor kinase gene baeS were identified among NWT isolates. Cefiderocol NWT isolates were more likely to be resistant to colistin than WT isolates (29% vs. 0%). Our findings suggest that no consistent antimicrobial resistance markers contribute to baseline cefiderocol resistance in CRE isolates and, rather, cefiderocol resistance results from a combination of heterogeneous mechanisms.
References: Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0217120. (PMID: 34031052)
Antimicrob Agents Chemother. 2020 Apr 21;64(5):. (PMID: 32071053)
Int J Antimicrob Agents. 2019 Apr;53(4):456-466. (PMID: 30471402)
Clin Infect Dis. 2020 Dec 17;71(10):2713-2716. (PMID: 32236408)
Front Pharmacol. 2021 Jan 14;11:578823. (PMID: 33628170)
Drug Resist Updat. 2010 Dec;13(6):151-71. (PMID: 20833577)
Infect Control Hosp Epidemiol. 2018 Jan;39(1):116-118. (PMID: 29202892)
J Bacteriol. 1990 Mar;172(3):1361-7. (PMID: 2407721)
Antimicrob Agents Chemother. 1997 May;41(5):1010-6. (PMID: 9145861)
Adv Exp Med Biol. 2019;1145:55-71. (PMID: 31364071)
Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2319-2327. (PMID: 28748397)
Antimicrob Agents Chemother. 2014 Aug;58(8):4762-6. (PMID: 24914122)
J Glob Antimicrob Resist. 2020 Sep;22:738-741. (PMID: 32702396)
Infect Dis (Auckl). 2016 Oct 11;9:45-52. (PMID: 27773991)
Antimicrob Agents Chemother. 2017 Dec 21;62(1):. (PMID: 29061741)
J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36. (PMID: 28375512)
Antimicrob Agents Chemother. 2018 Dec 21;63(1):. (PMID: 30373801)
J Clin Microbiol. 2008 Sep;46(9):3110-1. (PMID: 18632915)
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S529-S537. (PMID: 31724044)
Diagn Microbiol Infect Dis. 2020 May;97(1):115012. (PMID: 32081522)
Int J Antimicrob Agents. 2018 Feb;51(2):206-212. (PMID: 29111435)
Antimicrob Agents Chemother. 2020 Jun 23;64(7):. (PMID: 32284381)
Expert Rev Anti Infect Ther. 2019 Aug;17(8):571-582. (PMID: 31340665)
Antimicrob Agents Chemother. 1995 Mar;39(3):613-9. (PMID: 7793861)
Antimicrob Agents Chemother. 2018 Jan 25;62(2):. (PMID: 29158270)
Clin Lab Med. 2019 Sep;39(3):405-418. (PMID: 31383265)
Clin Microbiol Rev. 2015 Jul;28(3):565-91. (PMID: 25926236)
Antimicrob Agents Chemother. 2017 Aug 24;61(9):. (PMID: 28630181)
Clin Infect Dis. 2021 Jun 03;:. (PMID: 34079986)
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S538-S543. (PMID: 31724047)
Int J Antimicrob Agents. 2019 Feb;53(2):177-184. (PMID: 30395986)
Antimicrob Agents Chemother. 2017 Aug 24;61(9):. (PMID: 28630178)
J Clin Microbiol. 2020 Dec 17;59(1):. (PMID: 32938734)
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S544-S551. (PMID: 31724049)
Clin Infect Dis. 2019 Jun 18;69(1):1-11. (PMID: 30715222)
J Clin Microbiol. 2020 Jun 24;58(7):. (PMID: 32295890)
Pharmacology. 2018;101(5-6):278-284. (PMID: 29471305)
Clin Infect Dis. 2017 Feb 1;64(3):257-264. (PMID: 28013264)
Antimicrob Agents Chemother. 1987 Apr;31(4):497-504. (PMID: 3037997)
J Antimicrob Chemother. 2017 Jun 1;72(6):1704-1708. (PMID: 28369471)
معلومات مُعتمدة: R21 AI153580 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: carbapenem-resistant Enterobacterales; cefiderocol; mechanisms of resistance
المشرفين على المادة: 0 (Anti-Bacterial Agents)
0 (Cephalosporins)
EC 3.5.2.6 (beta-Lactamases)
تواريخ الأحداث: Date Created: 20211007 Date Completed: 20220228 Latest Revision: 20231213
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8885434
DOI: 10.1089/mdr.2021.0095
PMID: 34619049
قاعدة البيانات: MEDLINE
الوصف
تدمد:1931-8448
DOI:10.1089/mdr.2021.0095